156294-36-9

Basic information

• Product Name: Larotaxel
• Synonyms: Larotaxel;PNU 100940
• CAS NO: 156294-36-9
• Molecular Formula: C₄₅H₅₃NO₁₄
• Molecular Weight: 831.90062
• Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 156294-36-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 889.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.37
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 11.20±0.46(Predicted)
• CAS DataBase Reference: Larotaxel(CAS DataBase Reference)
• NIST Chemistry Reference: Larotaxel(156294-36-9)
• EPA Substance Registry System: Larotaxel(156294-36-9)

Safety Data

• Hazardous Substances Data: 156294-36-9(Hazardous Substances Data)

Usage

Description

Larotaxel, also known as RPR 109881A, is a taxane analog derived from the family of natural products known as taxanes. It exhibits a broad spectrum of activity and possesses a distinct toxicity profile, offering potential advantages in overcoming certain resistance mechanisms and penetrating the central nervous system (CNS).

Uses

Used in Anticancer Applications:
Larotaxel is used as a chemotherapeutic agent for the treatment of various types of cancer. It demonstrates a broad spectrum of activity, making it effective against a wide range of malignancies. Its unique toxicity profile and potential to overcome resistance mechanisms contribute to its effectiveness in treating cancer.
Used in Drug Delivery Systems:
Larotaxel is also used in the development of novel drug delivery systems to enhance its therapeutic efficacy and bioavailability. These systems aim to improve the delivery of Larotaxel to cancer cells, potentially increasing its effectiveness and reducing side effects. Various organic and metallic nanoparticles have been explored as carriers for Larotaxel delivery, with the goal of optimizing its pharmacokinetics and therapeutic outcomes.
Used in Central Nervous System (CNS) Applications:
Due to its potential to penetrate the CNS, Larotaxel is also being investigated for its use in treating cancers that affect the brain and other components of the central nervous system. This unique property sets it apart from other taxane analogs and may offer new treatment options for patients with CNS malignancies.

Upstream product

• 32981-86-5 10-deacetylbaccatin III 
• 27548-93-2 baccatin III 
• 158811-19-9 10-acetyl-7-trifluoromethanesulfonate baccatin III 
• 156294-33-6 7-deoxy-7β,8β-methanobaccatin III 
• 156294-35-8 (2α,3α,4α,5β,7α,10β,13α)-4,10-bis(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-11-en-2-yl benzoate 
• 31077-81-3 7-epi-baccatine III 
• 71629-92-0 10-deacetyl-7-epi-baccatin III 
• 131968-76-8 (+/-)-(3R,4S)-3-acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one 
• 101067-78-1 (+/-)-(3R,4S)-3-hydroxy-4-phenyl-N-(4-methoxyphenyl)azetidin-2-one 
• 100-52-7 benzaldehyde 

Downstream Products

• 1308398-58-4 larotaxel β-alanine glycolate 
• 1321582-53-9 larotaxel MMT-aminoethyldithioethyl carbonate 
• 1308398-56-2 larotaxel Cbz-β-alanine glycolate 
• 1308398-61-9 larotaxel aminoethoxyethoxy acetate methansulfonate 
• 1308398-59-5 larotaxel Cbz-aminoethoxyethoxy acetate 
• 1308398-55-1 larotaxel glycinate methansulfonate 
• 1308398-64-2 larotaxel aminohexanoate methanosulfonate 
• 1308398-62-0 larotaxel Cbz-aminohexanoate 
• 1308398-53-9 larotaxel Cbz-glycinate 

Relevant articles and documents

A semi-synthetic taxane derivative and its preparation method and application

The invention discloses a semi-synthetic taxane derivative. An anti-tumor effect test shows that the semi-synthetic taxane derivative has relatively good anti-tumor activity on a human lung adenocarcinoma cell line A549, a human breast cancer cell line MCF-7, a human glioblastoma cell line U251, a human pancreatic cancer cell line PANC-1, a human colon cancer cell line HCT116 and a human non-small lung cancer cell line H460. The semi-synthetic taxane derivative can be used for preparing anti-tumor drugs.

PROCESS FOR PREPARING TAXOIDS FROM BACCATIN DERIVATIVES USING LEWIS ACID CATALYST

The present invention relates to a process of preparing a taxoid (X) by reacting a protected baccatin derivative (B) with a β-lactam (C) in the presence of one or more Lewis acids and a base agent. The present invention also relates to a process of preparing the protected baccatin derivative (B) from a baccatin derivative (A) comprising a protection reaction catalyzed by one or more Lewis acids with an optional base agent.